File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/00005537-200303000-00020
- Scopus: eid_2-s2.0-0037337242
- PMID: 12616204
- WOS: WOS:000181389300020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Olfactory neuroblastoma: Past, present, and future?
Title | Olfactory neuroblastoma: Past, present, and future? |
---|---|
Authors | |
Keywords | Craniofacial resection Esthesioneuroblastoma Olfactory neuroblastoma |
Issue Date | 2003 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.laryngoscope.com/ |
Citation | Laryngoscope, 2003, v. 113 n. 3, p. 502-507 How to Cite? |
Abstract | Objective: To consider the long-term survival and outcomes in patients with olfactory neuroblastoma undergoing craniofacial resection. Study Design: A single-center prospective cohort study. Methods: All patients with olfactory neuroblastoma treated in a 23-year period with craniofacial resection (with or without radiotherapy) were analyzed; a multivariate analysis was included. Results: Forty-two patients aged 12 to 70 years were assessed, 83% of whom had received no preceding treatment. Craniofacial resection was used in all cases, combined with radiotherapy in 24 patients (57%). Duration of follow-up ranged from 2 to 206 months (mean follow-up period, 57 mo). The disease-free actuarial survival and overall survival were 77% and 61% at 5 years and 53% and 42% at 10 years, respectively. A Cox regression analysis identified intracranial extension and orbital involvement as independent factors affecting outcome. Conclusion: Craniofacial resection combined with radiotherapy offers the gold standard of care against which other approaches such as endoscopic resection must be judged. |
Persistent Identifier | http://hdl.handle.net/10722/172823 |
ISSN | 2023 Impact Factor: 2.2 2023 SCImago Journal Rankings: 1.128 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lund, VJ | en_US |
dc.contributor.author | Howard, D | en_US |
dc.contributor.author | Wei, W | en_US |
dc.contributor.author | Spittle, M | en_US |
dc.date.accessioned | 2012-10-30T06:25:07Z | - |
dc.date.available | 2012-10-30T06:25:07Z | - |
dc.date.issued | 2003 | en_US |
dc.identifier.citation | Laryngoscope, 2003, v. 113 n. 3, p. 502-507 | en_US |
dc.identifier.issn | 0023-852X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/172823 | - |
dc.description.abstract | Objective: To consider the long-term survival and outcomes in patients with olfactory neuroblastoma undergoing craniofacial resection. Study Design: A single-center prospective cohort study. Methods: All patients with olfactory neuroblastoma treated in a 23-year period with craniofacial resection (with or without radiotherapy) were analyzed; a multivariate analysis was included. Results: Forty-two patients aged 12 to 70 years were assessed, 83% of whom had received no preceding treatment. Craniofacial resection was used in all cases, combined with radiotherapy in 24 patients (57%). Duration of follow-up ranged from 2 to 206 months (mean follow-up period, 57 mo). The disease-free actuarial survival and overall survival were 77% and 61% at 5 years and 53% and 42% at 10 years, respectively. A Cox regression analysis identified intracranial extension and orbital involvement as independent factors affecting outcome. Conclusion: Craniofacial resection combined with radiotherapy offers the gold standard of care against which other approaches such as endoscopic resection must be judged. | en_US |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.laryngoscope.com/ | en_US |
dc.relation.ispartof | Laryngoscope | en_US |
dc.subject | Craniofacial resection | - |
dc.subject | Esthesioneuroblastoma | - |
dc.subject | Olfactory neuroblastoma | - |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Cohort Studies | en_US |
dc.subject.mesh | Combined Modality Therapy | en_US |
dc.subject.mesh | Esthesioneuroblastoma, Olfactory - Pathology - Radiotherapy - Surgery | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-Up Studies | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Magnetic Resonance Imaging | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Multivariate Analysis | en_US |
dc.subject.mesh | Nasal Cavity - Pathology - Radiation Effects - Surgery | en_US |
dc.subject.mesh | Nose Neoplasms - Pathology - Radiotherapy - Surgery | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Surgical Procedures, Operative - Methods | en_US |
dc.subject.mesh | Survivors | en_US |
dc.title | Olfactory neuroblastoma: Past, present, and future? | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wei, W: hrmswwi@hku.hk | en_US |
dc.identifier.authority | Wei, W=rp00323 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1097/00005537-200303000-00020 | en_US |
dc.identifier.pmid | 12616204 | - |
dc.identifier.scopus | eid_2-s2.0-0037337242 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0037337242&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 113 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 502 | en_US |
dc.identifier.epage | 507 | en_US |
dc.identifier.isi | WOS:000181389300020 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Lund, VJ=7102840344 | en_US |
dc.identifier.scopusauthorid | Howard, D=7202305361 | en_US |
dc.identifier.scopusauthorid | Wei, W=7403321552 | en_US |
dc.identifier.scopusauthorid | Spittle, M=7005469643 | en_US |
dc.identifier.issnl | 0023-852X | - |